U.S. Markets closed

Top Ranked Momentum Stocks to Buy for March 20th

Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 20th:

Select Interior Concepts, Inc. (SIC): This interior building products installer has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.5% over the last 60 days.

SELECT INT CONC Price and Consensus

SELECT INT CONC Price and Consensus

SELECT INT CONC price-consensus-chart | SELECT INT CONC Quote

Select Interior Concepts’ shares gained 12.2% over the last one month against the S&P 500’s rise of 1.7%. The company possesses a Momentum Score of A.

SELECT INT CONC Price

SELECT INT CONC Price

SELECT INT CONC price | SELECT INT CONC Quote

Clarus Corporation (CLAR): This outdoor equipment and lifestyle products manufacturer has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 3.9% over the last 60 days.

Clarus Corporation Price and Consensus

Clarus Corporation Price and Consensus

Clarus Corporation price-consensus-chart | Clarus Corporation Quote

Clarus’ shares gained 3.2% over the last one month. The company possesses a Momentum Score of B.

Clarus Corporation Price

Clarus Corporation Price

Clarus Corporation price | Clarus Corporation Quote

Dr. Reddy's Laboratories Limited (RDY): This integrated pharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 10.1% over the last 60 days.

Dr. Reddy's Laboratories Ltd Price and Consensus

Dr. Reddy's Laboratories Ltd Price and Consensus

Dr. Reddy's Laboratories Ltd price-consensus-chart | Dr. Reddy's Laboratories Ltd Quote

Dr. Reddy's shares gained 10.6% over the last one month. The company possesses a Momentum Score of B.

Dr. Reddy's Laboratories Ltd Price

Dr. Reddy's Laboratories Ltd Price

Dr. Reddy's Laboratories Ltd price | Dr. Reddy's Laboratories Ltd Quote

Genocea Biosciences, Inc. (GNCA): This biopharmaceutical company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 38.6% over the last 60 days.

Genocea Biosciences, Inc. Price and Consensus

Genocea Biosciences, Inc. Price and Consensus

Genocea Biosciences, Inc. price-consensus-chart | Genocea Biosciences, Inc. Quote

Genocea Biosciences’ shares gained 43.4% over the last one month. The company possesses a Momentum Score of A.

Genocea Biosciences, Inc. Price

Genocea Biosciences, Inc. Price

Genocea Biosciences, Inc. price | Genocea Biosciences, Inc. Quote

See the full list of top ranked stocks here.

Learn more about the Momentum score and how it is calculated here.

This Could Be the Fastest Way to Grow Wealth in 2019

Research indicates one sector is poised to deliver a crop of the best-performing stocks you'll find anywhere in the market. Breaking news in this space frequently creates quick double- and triple-digit profit opportunities.

These companies are changing the world – and owning their stocks could transform your portfolio in 2019 and beyond. Recent trades from this sector have generated +98%, +119% and +164% gains in as little as 1 month.

Click here to see these breakthrough stocks now >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
SELECT INT CONC (SIC) : Free Stock Analysis Report
 
Dr. Reddy's Laboratories Ltd (RDY) : Free Stock Analysis Report
 
Genocea Biosciences, Inc. (GNCA) : Free Stock Analysis Report
 
Clarus Corporation (CLAR) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research